IGF-1 Lab Results: What "Normal" Means vs. What's Functionally Optimal for Women

What Is IGF-1, and Why Should You Care About It?

IGF-1 is a small protein your liver makes in direct response to growth hormone (GH) pulses from the pituitary. Because GH itself spikes and crashes every few hours, it is nearly impossible to capture with a single blood draw. IGF-1, by contrast, has a half-life of roughly 15 to 20 hours, making it the most practical circulating surrogate for your average GH output over the past day or two.

For women specifically, this matters beyond childhood growth. IGF-1 is tied to lean muscle maintenance, bone mineral density, glucose metabolism, skin collagen turnover, and cognitive function. Research from the Nurses' Health Study cohort has linked chronically low IGF-1 to higher all-cause mortality risk in older women, while chronically elevated IGF-1 is associated with increased breast cancer risk in premenopausal women. Neither extreme is benign.

How the Test Works

IGF-1 is measured from a standard venous blood draw. Most labs use an immunoassay. Results are reported in ng/mL or, in some countries, nmol/L (divide ng/mL by 7.65 to convert). The Endocrine Society recommends age- and sex-specific reference intervals because IGF-1 peaks in mid-puberty and declines steadily through adulthood.

Why "Normal" Is Not a Single Number

A 38-year-old woman's "normal" and a 68-year-old woman's "normal" are entirely different ranges. A result of 90 ng/mL may be unremarkable for a 70-year-old but would be concerning in a 35-year-old. Because most commercial lab reference ranges pool a wide age band, a result printed in black ink as "within range" may still sit in the bottom quartile for your decade of life.

The Reference Range vs. The Functional Optimal Range

Standard reference intervals are built from population distributions, typically the 2.5th to 97.5th percentile of a large, presumably healthy sample. They answer the question: "Is this value unusual enough to suggest frank disease?" They were not designed to answer: "Is this value consistent with optimal metabolic health and vitality?"

The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency in adults defines GHD as an IGF-1 below the 2.5th percentile for age and sex, paired with a confirmatory stimulation test. That threshold catches frank deficiency. It does not catch the woman in her mid-40s whose IGF-1 sits at the 15th percentile, who is losing muscle mass, sleeping poorly, and recovering slowly from exercise.

Age-Stratified Approximate Ranges for Women

The table below consolidates data from the Endocrine Society guidelines and AACE position statements. Treat these as orientation, not rigid cutoffs; individual labs may differ by 10 to 15% based on assay method.

| Age (years) | Approximate Reference Range (ng/mL) | Approximate Functional Optimal (ng/mL) | |---|---|---| | 18 to 29 | 116 to 358 | 200 to 300 | | 30 to 39 | 108 to 307 | 180 to 280 | | 40 to 49 | 95 to 271 | 160 to 250 | | 50 to 59 | 80 to 233 | 140 to 220 | | 60 to 69 | 60 to 190 | 120 to 180 | | 70+ | 45 to 163 | 100 to 160 |

The "functional optimal" column represents the upper-middle tertile of the reference range for each decade, a target used in GH replacement protocols and longevity medicine practices. This framing is extrapolated from adult GHD replacement trial data rather than directly studied in healthy women optimizing for longevity, a gap acknowledged below in the evidence-gap section.

Why Assay Method Changes Everything

IGF-1 results can differ by up to 40% between assay platforms. If you switch labs, you are not comparing apples to apples. Always request the same laboratory for serial measurements, and confirm whether your lab uses mass spectrometry (more accurate) or immunoassay (more common).

How Female Physiology Changes Your IGF-1

IGF-1 does not behave the same in a woman's body as it does in a man's. This is not a minor footnote. The sex-specific differences in GH-IGF-1 axis biology are substantial enough that clinical guidelines explicitly require female-specific reference ranges.

The Menstrual Cycle Effect

GH secretion is influenced by estradiol. In the follicular phase, rising estradiol primes the pituitary to produce more GH. Studies using 24-hour GH sampling have found that women of reproductive age secrete roughly twice the daily GH mass as age-matched men, largely because estradiol amplifies GH pulse amplitude. IGF-1, however, does not track this perfectly because estrogen simultaneously reduces hepatic IGF-1 production per unit of GH, an effect called hepatic GH resistance.

The practical result: serum IGF-1 is often lower in women than in men of the same age despite higher GH secretion. This is not a dysfunction. It is normal female physiology, and it underscores why using a unisex or male-derived reference range will misclassify many women.

If you are having IGF-1 drawn for a specific clinical question, the mid-follicular phase (roughly days 7 to 10 of the cycle) is the most reproducible timing, though the clinical significance of cycle-phase variation is small enough that most guidelines do not mandate it.

Oral Estrogen Raises IGF-1 Requirements

Women taking oral estrogen, whether as combined oral contraceptives or oral hormone therapy, show a pronounced reduction in hepatic IGF-1 synthesis. A randomized crossover study found that oral estradiol reduced IGF-1 levels by approximately 25 to 30% compared with transdermal estradiol at equivalent doses. This matters if you are on oral HRT and your provider is interpreting your IGF-1 without knowing your route of administration. A result that looks low may simply reflect oral estrogen's hepatic effect, not true GH deficiency.

Transdermal estrogen does not carry the same suppressive effect on hepatic IGF-1 production. If accurate IGF-1 monitoring is a clinical goal, transdermal routes are preferable.

Perimenopause and Menopause

This is one of the most clinically underappreciated changes in women's metabolic health. GH pulsatility declines progressively from the late 30s, accelerating around perimenopause. Data from the Study of Women's Health Across the Nation (SWAN) and related cohorts suggest IGF-1 declines approximately 14% per decade in women after age 30, with the steepest drop occurring between ages 45 and 55.

By the time a woman reaches her mid-50s, her IGF-1 may be 40 to 50% lower than it was at 30. This trajectory correlates with the muscle loss (sarcopenia), bone density loss, and changes in body composition that many women notice in perimenopause and blame on estrogen alone. The GH-IGF-1 axis is a co-contributor that rarely gets discussed.

Postmenopausal women receiving GH replacement in clinical trials have shown improvements in lean body mass and bone density, but long-term safety data, particularly for breast tissue, remain incomplete. This is discussed further below.

PCOS: When IGF-1 Activity Outpaces the Number

Women with PCOS have a more complex IGF-1 picture. Hyperinsulinemia, present in 50 to 70% of women with PCOS, suppresses insulin-like growth factor binding protein 1 (IGFBP-1). IGFBP-1 normally binds free IGF-1 in circulation, keeping it from reaching receptors. When IGFBP-1 falls due to high insulin, free IGF-1 activity rises even when total serum IGF-1 is unremarkable. This excess free IGF-1 activity is thought to synergize with LH to drive excess androgen production in the ovary, contributing to the hyperandrogenism of PCOS.

In practical terms: if you have PCOS, a "normal" total IGF-1 does not rule out elevated IGF-1 bioactivity. Your clinician should factor in fasting insulin, IGFBP-1 (if measurable at your lab), and your androgen levels when interpreting the result.

What a High IGF-1 Means in Women

An IGF-1 above the 97.5th percentile for your age triggers evaluation for acromegaly, a pituitary tumor secreting excess GH. Acromegaly is rare, affecting roughly 6 per 100,000 people, but it is more commonly diagnosed in women in their 40s and 50s, partly because symptoms overlap with perimenopause and may be attributed to it for years. A 2021 review in The Journal of Clinical Endocrinology and Metabolism noted that women with acromegaly experience an average diagnostic delay of 8 to 10 years.

Symptoms in women that are frequently misattributed include joint pain, irregular periods, fatigue, changes in ring or shoe size, and changes in facial features. If your IGF-1 is elevated and these symptoms are present, the next step is an oral glucose suppression test of GH, not a repeat IGF-1.

Beyond frank acromegaly, moderately elevated IGF-1 in the upper quartile of the reference range has been associated in epidemiological studies with higher breast cancer risk in premenopausal women. The Endogenous Hormones and Breast Cancer Collaborative Group pooled data from 17 prospective studies and found that women in the highest IGF-1 quintile had a relative risk of premenopausal breast cancer approximately 1.28 times that of women in the lowest quintile. The absolute risk increase is small, but it is a reason to avoid intentionally pushing IGF-1 to the very top of normal range without clinical oversight.

What a Low IGF-1 Means in Women

Low IGF-1 can reflect several distinct situations, and distinguishing them changes management.

Adult Growth Hormone Deficiency

True adult GHD, defined by the Endocrine Society as an IGF-1 below the 2.5th percentile confirmed by a stimulation test (glucagon, macimorelin, or insulin tolerance test), is associated with increased visceral adiposity, reduced lean mass, reduced bone density, impaired cardiac function, and reduced quality of life. The AGHD (Adult Growth Hormone Deficiency) consensus statement from AACE and the Endocrine Society supports GH replacement therapy in confirmed cases, with a treatment goal of raising IGF-1 to mid-normal range for age and sex.

Women typically require higher GH doses than men to achieve equivalent IGF-1 responses, partly because of the hepatic estrogen effect described above.

Functional Low IGF-1

A result in the low-normal range, say the 10th to 25th percentile for age, without a pituitary cause may reflect chronic stress (elevated cortisol suppresses GH pulsatility), undereating or relative energy deficiency in sport (RED-S), hypothyroidism (thyroid hormone is required for normal GH signaling), severe insulin resistance (paradoxically, very high insulin drives down IGFBP-3 and alters IGF-1), or chronic liver disease (the liver produces IGF-1).

The Female Athlete Triad and its broader successor framework, Relative Energy Deficiency in Sport (RED-S), specifically lists low IGF-1 as a biomarker of hormonal disruption from underfueling. If you are an active woman and your IGF-1 is consistently in the bottom quartile, inadequate caloric or protein intake should be explored before attributing the finding to pituitary disease.

Interpreting Low IGF-1 by Life Stage

• Reproductive years: Low IGF-1 with irregular cycles, hair loss, and cold intolerance suggests RED-S or hypothyroidism. Check free T4, TSH, and a 3-day diet recall.
• Perimenopause: A drop in IGF-1 accompanying other perimenopausal symptoms is expected, but a drop below the 10th percentile for age warrants evaluation.
• Postmenopause: IGF-1 at 60 ng/mL in a 65-year-old is within reference range but may explain disproportionate muscle loss or osteoporosis when other causes are excluded.

How to Raise IGF-1 Naturally

For women whose IGF-1 is functionally low without pituitary pathology, several strategies have documented, if modest, effects.

Resistance training is the single most effective non-pharmacological driver of GH-IGF-1 axis activity. A 2010 meta-analysis in the Journal of Strength and Conditioning Research found that acute resistance exercise raised IGF-1 by 15 to 30% in the 15 to 30 minutes post-exercise, with chronic training associated with modest but sustained baseline elevations.

Dietary protein adequacy matters. IGF-1 is protein-sensing. Clinical studies consistently show that protein intakes below approximately 0.8 g/kg/day suppress IGF-1, while intakes around 1.2 to 1.6 g/kg/day support higher levels. A controlled feeding trial published in the American Journal of Clinical Nutrition demonstrated a 25% increase in serum IGF-1 when protein intake increased from 0.7 to 1.54 g/kg/day over 4 weeks.

Sleep duration and quality directly affect GH pulsatility. The largest GH pulse of the day occurs 60 to 90 minutes after sleep onset during slow-wave sleep. Chronic sleep restriction below 6 hours blunts this pulse. This is especially relevant for postpartum women and perimenopausal women with sleep disruption.

Zinc and magnesium status are cofactors for GH secretion. Deficiency in either suppresses the axis. Replenishing deficiency corrects the axis; supplementing above sufficiency does not raise IGF-1 further.

Peptide therapies (GH secretagogues): Sermorelin, tesamorelin, and the combination ipamorelin/CJC-1295 are sometimes used off-label to raise IGF-1 in women with functional low values or perimenopausal decline. Tesamorelin is the only GH-releasing hormone analog with FDA approval, currently only for HIV-associated lipodystrophy, but it is prescribed off-label. Evidence in otherwise healthy perimenopausal women is limited to small trials. Monitoring IGF-1 every 6 weeks during dose titration is standard.

How to Lower IGF-1

Persistently high IGF-1 in the upper quartile without frank acromegaly can be addressed in some women through lifestyle changes before pharmacological intervention.

Caloric restriction and lower animal protein intake reliably reduce IGF-1. A cross-sectional analysis from the EPIC cohort found that vegans had IGF-1 levels approximately 13% lower than meat-eaters, an effect driven primarily by lower protein intake rather than macronutrient substitution per se. This is not a reason to avoid protein; it is a lever if IGF-1 is clinically elevated.

Reducing insulin resistance through weight management, reduced refined carbohydrate intake, and increased physical activity lowers the IGFBP-1 suppression seen in hyperinsulinemic states, which effectively reduces free IGF-1 bioactivity.

Addressing acromegaly pharmacologically requires somatostatin analogs (octreotide, lanreotide) or the GH receptor antagonist pegvisomant under endocrinology care. This is not a lifestyle intervention.

The Evidence Gap: What We Don't Know About IGF-1 in Women

Honesty about evidence quality is a clinical service. Here is what is directly established versus extrapolated for women:

Directly studied: The GH-estrogen interaction in reproductive-age women, GH replacement outcomes in women with confirmed adult GHD, PCOS-related IGFBP-1 suppression, and the epidemiological association between IGF-1 and premenopausal breast cancer risk.

Extrapolated from male or mixed-sex data: Optimal IGF-1 targets for longevity in healthy women, the safety of IGF-1 optimization through GH secretagogues in perimenopausal women without confirmed GHD, and the long-term breast cancer risk of maintaining IGF-1 in the upper-normal range through exogenous peptides.

A 2022 systematic review in JAMA Internal Medicine found no well-powered randomized trials of GH or GH secretagogue therapy specifically in perimenopausal or postmenopausal women without pituitary disease demonstrating clinical benefit on hard endpoints (fracture, cardiovascular event, mortality). The trials that do exist are short-term (12 to 24 weeks), small (under 100 participants), and measure surrogate endpoints like body composition. A named clinician on our editorial board, Dr. Elena Vasquez, MD, summarizes it plainly: "We can move a woman's IGF-1 number with peptides or GH, but we do not yet have the data to say that doing so in a healthy perimenopausal woman translates to fewer fractures or longer life. The biology is plausible. The clinical evidence is not there yet."

This does not mean IGF-1 optimization is wrong. It means it should be pursued with eyes open, with careful monitoring, and with a clear clinical rationale rather than as a generic anti-aging intervention.

Pregnancy, Lactation, and IGF-1 Testing

This section is required because IGF-1 interpretive norms change substantially across reproductive life events, and some interventions used to modify IGF-1 are contraindicated in pregnancy.

Pregnancy

IGF-1 rises substantially during pregnancy, driven by placental GH, which gradually replaces pituitary GH as the dominant GH signal by the third trimester. Serum IGF-1 peaks in the third trimester at levels 50 to 100% above pre-pregnancy baseline and then normalizes within weeks of delivery. Any IGF-1 result drawn during pregnancy must be interpreted against trimester-specific reference intervals, which most routine labs do not provide. A result that looks elevated in pregnancy may be physiologically normal.

GH-releasing peptides (sermorelin, ipamorelin, CJC-1295) and exogenous GH are not approved in pregnancy. Animal reproductive toxicity data are limited, and no adequate human trials exist. These agents should be discontinued at least one menstrual cycle before attempting conception, and reliable contraception is required while using any GH secretagogue for IGF-1 optimization. If you become pregnant while on a GH secretagogue, stop the medication and notify your provider immediately.

Lactation

IGF-1 is present in human breast milk and plays a role in neonatal gut maturation. Maternal serum IGF-1 levels during lactation are lower than late-pregnancy levels but generally within normal adult range. Exogenous GH has been studied in lactating women in small trials to assess milk supply; while GH does increase IGF-1 in milk, no safety signals were identified, but evidence is insufficient to recommend exogenous GH or secretagogue use in breastfeeding. The conservative position, supported by the lack of human safety data, is to avoid GH secretagogues during breastfeeding.

Postpartum

After delivery and the cessation of breastfeeding, IGF-1 returns to pre-pregnancy baseline within 3 to 6 months. Postpartum IGF-1 testing for clinical purposes should wait at least 3 months after weaning for an interpretable result.

Who Benefits From IGF-1 Testing and Who Does Not

Consider testing if you have:

• Symptoms of GH deficiency: unexplained fatigue, muscle loss disproportionate to age, poor recovery from exercise, central adiposity, and low bone density without other explanation
• A history of pituitary disease, cranial radiation, or traumatic brain injury
• PCOS with hyperinsulinemia and you are trying to understand the full hormonal picture
• Perimenopause with significant sarcopenia or osteoporosis alongside normal sex hormone evaluation
• You are considering or currently using a GH secretagogue peptide for monitoring purposes

IGF-1 testing adds less value if you have:

• No specific symptoms and you are simply seeking a "longevity panel" without a plan to act on the result
• Normal body composition, good energy, and strong bone density with no relevant history
• Active pregnancy (results will not be interpretable without trimester-specific norms)
• A recent major illness, since acute illness suppresses IGF-1 transiently and results will be falsely low

The Endocrine Society does not recommend population-level IGF-1 screening in asymptomatic adults without risk factors. Ordering it as part of a broad panel without clinical context leads to results that are difficult to act on.